Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
OrganOmics logo — Human Tissues for Human Therapeutics

OrganOmics

Human Tissues for Human Therapeutics

Founded 2021 United States Seattle, United States 2 employees Non Equity Assistance Biotechnology, Health Care +1

General Information

Company Name OrganOmics
Founded Year 2021
Location United States Seattle, United States
Employees 2
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Non Equity Assistance
Social

BounceWatch is an independent company data service, not affiliated with OrganOmics. To contact OrganOmics, visit organomicsbio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does OrganOmics compare?

A PDF of OrganOmics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting OrganOmics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About OrganOmics

OrganOmics is a biotechnology startup based in the United States, founded in 2021 with the slogan "Human Tissues for Human Therapeutics." The company is revolutionizing preclinical drug discovery with their cutting-edge live human brain tissue models derived from stem cells, as well as patient-derived cancer tissue to induce realistic cancer pathology in collaboration with neurosurgeons. Their patented microfluidic platform automates assays, detailing drug responses of thousands of tissues and generating vast, high-content data. This data is processed through artificial intelligence to predict the clinical outcomes of candidate drugs. The last investment in OrganOmics was a Non-Equity Assistance investment at 15 February 2021, and it was provided by CITRIS Foundry. This innovative approach to preclinical drug discovery in the field of biotechnology and healthcare has attracted attention from investors and stakeholders. OrganOmics demonstrates impressive potential in shaping the future of drug discovery by leveraging advanced technology and breakthrough scientific models. With its focus on harnessing the power of engineered tissue and AI, the company stands as a promising player in the biotechnology and healthcare industries. As the demand for advanced preclinical drug discovery solutions grows, OrganOmics holds significant promise for generating impactful outcomes for the biotechnology and healthcare sectors.

Business keywords: preclinical drug discovery, engineered tissue, stem cell technology, cancer pathology, microfluidic platform, high-content data, precision medicine, drug response, therapeutics, clinical outcomes, neuroscience, biomedical engineering

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Non Equity Assistance Undisclosed 1
CITRIS Foundry
CITRIS Foundry
15 Feb 2021

OrganOmics Alternatives & Competitors

View All Alternatives
OrganOmics vs
InvivoSciences® Inc.
InvivoSciences® Inc. United States

Discovery with Human touch

Non Equity Assistance
4 employees
Biotechnology, Health Care
OrganOmics vs
Center for Discovery and Innovation
Center for Discovery and Innovation United States

Scientists transforming today’s ideas into tomorrow’s cures.

111 employees
Biotechnology, Health Care
OrganOmics vs
Cellular Dynamics International
Cellular Dynamics International

Harness the Power of Fully Functional Human Cells for Innovative Drug Discovery and Therapeutics.

Debt Financing
Biotechnology, Health Care
View all alternatives

FAQ About OrganOmics

Human Tissues for Human Therapeutics
OrganOmics was founded in 2021.
OrganOmics is headquartered in Seattle, United States.
OrganOmics operates in Biotechnology, Health Care and Health and Wellness. Its work centres on preclinical drug discovery, engineered tissue, stem cell technology and cancer pathology.
OrganOmics has approximately 2 employees.
OrganOmics has completed 1 funding round. The latest funding stage is Non Equity Assistance.
Top alternatives and competitors to OrganOmics include InvivoSciences® Inc., Center for Discovery and Innovation , Cellular Dynamics International, Kayothera, Cairn Biosciences. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
OrganOmics and InvivoSciences® Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for OrganOmics, https://bouncewatch.com/company/organomics, updated 14 January 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes